Log in

NYSEAMERICAN:TRXCTransEnterix Stock Price, Forecast & News

$0.35
-0.02 (-5.45 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.34
Now: $0.35
$0.38
50-Day Range N/A
52-Week Range
$0.28
Now: $0.35
$25.22
Volume6.77 million shs
Average Volume2.54 million shs
Market Capitalization$17.99 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Read More
TransEnterix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$17.99 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.

TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of TransEnterix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for TransEnterix.

When is TransEnterix's next earnings date?

TransEnterix is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransEnterix.

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) posted its earnings results on Thursday, May, 14th. The medical instruments supplier reported ($0.41) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.12. The medical instruments supplier earned $0.60 million during the quarter, compared to the consensus estimate of $0.54 million. View TransEnterix's earnings history.

What price target have analysts set for TRXC?

1 brokers have issued 1-year target prices for TransEnterix's shares. Their forecasts range from $1.00 to $1.00. On average, they expect TransEnterix's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 188.2% from the stock's current price. View analysts' price targets for TransEnterix.

Has TransEnterix been receiving favorable news coverage?

News coverage about TRXC stock has been trending neutral this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. TransEnterix earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the next few days. View the latest news about TransEnterix.

Are investors shorting TransEnterix?

TransEnterix saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 2,160,000 shares, a decrease of 10.7% from the May 31st total of 2,420,000 shares. Based on an average daily volume of 2,640,000 shares, the short-interest ratio is presently 0.8 days. Approximately 5.0% of the company's stock are short sold. View TransEnterix's Current Options Chain.

Who are some of TransEnterix's key competitors?

What other stocks do shareholders of TransEnterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), Geron (GERN), NVIDIA (NVDA), Advanced Micro Devices (AMD) and Opko Health (OPK).

Who are TransEnterix's key executives?

TransEnterix's management team includes the following people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $0.35.

How big of a company is TransEnterix?

TransEnterix has a market capitalization of $17.99 million.

What is TransEnterix's official website?

The official website for TransEnterix is www.transenterix.com.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.